UCSF Helen Diller Family Comprehensive Cancer Center

Name

UCSF Helen Diller Family Comprehensive Cancer Center

Legal name

UCSF Helen Diller Family Comprehensive Cancer Center

Website

https://cancer.ucsf.edu

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

5,001–10,000 employees

Ownership category

akta.pro rank

Product category

Academic Cancer Treatment and Research Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Scientific Research and Development Services (5417), Diagnostic Imaging Centers (621512)

SIC

Services-Health Services (8000), Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM)

akta.pro secondary industries

Public Research Universities with Academic Medical Centers (AMCs) (EDAHAAAC), Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI), Medical Oncology (HLAKAFAB)

Keywords

• Cancer treatment services
• Oncology clinical trials
• Precision medicine research
• Translational cancer research
• Immunotherapy development

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Research Grants and NIH/NCI Funding: Federal research funding from NIH and NCI for cancer research programs, clinical trials, and specialized initiatives
2. Philanthropic Donations: Major philanthropic initiatives including the $200 million Weill Cancer Hub West initiative with matching gifts
3. Clinical Services Revenue: Revenue from patient care services including clinical trials participation, cancer treatment, and specialized oncology care

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

UCSF Helen Diller Family Comprehensive Cancer Center is an NCI-designated comprehensive cancer center that delivers integrated cancer patient care, oncology clinical trials across all major cancer types, and translational research programs spanning precision medicine, immunotherapy, molecular oncology, and cancer data science. Its offerings combine direct clinical services, multi-phase clinical trial enrollment, and discovery research supported by NIH/NCI grants and philanthropic funding.

Product overview

UCSF Helen Diller Family Comprehensive Cancer Center is an NCI-designated comprehensive cancer center offering an integrated portfolio of cancer care services and research programs. The center provides clinical trials across all major cancer types (breast, prostate, gastrointestinal, lung, brain, melanoma, pancreatic, sarcoma, gynecologic, hematologic malignancies), supported by dedicated research programs including Molecular Oncology, Prostate Cancer, Immunotherapy, Cancer Data Science, and Precision Medicine. Key services include the Cancer Registry for population-based surveillance, the iMPACT program for clinical trial access equity, and the online clinical trials search portal. Research initiatives include the Benioff Initiative for Prostate Cancer Research (2019) and participation in the Weill Cancer Hub West partnership with Stanford (2025) and Caris Precision Oncology Alliance (2026). The center also produces CureTalks podcasts for patient education.

Differentiator

Problem solved

Functional benefit

Brands

• Weill Cancer Hub West: A $200 million partnership between Stanford Cancer Institute and UCSF focusing on multidisciplinary research including precision nutrition, AI-driven personalized cancer treatment, cellular therapies for solid tumors, and in-body immune cell engineering.

Products and services

• Clinical Trials Program Comprehensive clinical trials program offering Phase I–III studies across multiple cancer types, testing new treatments, prevention strategies, screening methods, and quality-of-life interventions; available to patients across all major cancer types.
• Cancer Registry Population-based cancer registry tracking cancer incidence and outcomes in the San Francisco Bay Area, contributing to national cancer surveillance and supporting research quality initiatives.
• iMPACT Program Improving Patient Access to Cancer Clinical Trials (iMPACT) is a 3-year pilot study providing sliding scale financial reimbursement for ancillary expenses (gas, parking, flights, hotels, transportation) to improve enrollment, retention, minority participation, and equitable access in oncology trials.
• Cancer Clinical Trials Search Portal Online portal (ClinicalTrials.UCSF.edu) enabling patients to search and find cancer clinical trials at UCSF across multiple cancer types, with filtering by cancer type and recruitment status.
• Precision Medicine Program Research priority area focused on using genomic and molecular profiling to guide individualized cancer treatment decisions, including participation in the Caris Precision Oncology Alliance.
• Immunotherapy Program Research priority area developing and testing immunotherapies including CAR-T cell therapies, immune checkpoint inhibitors, and novel cellular therapeutics for cancer treatment.
• Cancer Data Science Program Research priority area applying computational and analytical methods to cancer data for discovery and precision medicine applications.
• Molecular Oncology Program Research program (107+ members) discovering, developing, and translating novel preventive and therapeutic strategies and biomarkers through research spanning basic science to clinical applications.
• Prostate Cancer Program Research program (54+ members) using a team approach to advance understanding of tumor biology and drive translation into more effective and targeted prostate cancer treatment.
• Benioff Initiative for Prostate Cancer Research Initiative launched in 2019 to understand fundamental biology of aggressive prostate cancer and develop strategies leading to cure for metastatic disease through molecular mechanism-informed therapy approaches; has generated 530+ publications, >13,000 citations, $41M in additional NIH grants, and a 2024 Prostate Cancer SPORE award.

Quantifiable outcome

• 530+ publications and >13,000 citations by BIPCR investigators since 2020
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature5 records

Partnerships

Four partnerships are on record, tiered core, flagship and minor.

• Caris Life SciencescoreStrategic or Co-development Partner · 17 April 2026UCSF Helen Diller Family Comprehensive Cancer Center joined the Caris Precision Oncology Alliance, a global network of leading cancer centers collaborating on precision oncology and biomarker-driven research. The alliance leverages Caris' AI-driven molecular profiling platform and one of the industry's largest multimodal databases to accelerate cancer discoveries and translate findings into personalized patient care.
• Stanford Cancer InstituteflagshipStrategic or Co-development Partner · 1 January 2025The Weill family launched a $200 million initiative for the Weill Cancer Hub West, a partnership between Stanford Cancer Institute and UCSF. Both institutions committed to raise $50 million each in matching gifts over 10 years. The hub supports multiple multidisciplinary research projects including precision nutrition, AI-driven personalized cancer treatment, cellular therapies for solid tumors, and in-body immune cell engineering.
• Lazarex Cancer FoundationcoreStrategic or Co-development Partner · 15 April 2019UCSF collaborates with Lazarex Cancer Foundation on the iMPACT (Improving Patient Access to Cancer Clinical Trials) study, a 3-year pilot program providing sliding scale financial reimbursement for ancillary expenses associated with clinical trial participation. The program aims to improve enrollment, retention, minority participation, and equitable access in oncology trials.
• University of Southern CaliforniaminorStrategic or Co-development Partner · 15 April 2019Clinical trial collaboration for the iMPACT study, following UCSF launch, USC became the second site for the study before rolling out to other institutions nationwide.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Market position

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/ucsfcancer
• YouTubeyoutube.com/c/UCSFCancer
• Facebookfacebook.com/ucsfcancercenter
• LinkedInlinkedin.com/company/undefined

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about UCSF Helen Diller Family Comprehensive Cancer Center